Johnson & Johnson $JNJ Stock: SVB Wealth LLC Trims Holdings

SVB Wealth LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 10.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,662 shares of the company’s stock after selling 2,810 shares during the quarter. SVB Wealth LLC’s holdings in Johnson & Johnson were worth $6,529,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. CKW Financial Group lifted its stake in shares of Johnson & Johnson by 0.9% in the third quarter. CKW Financial Group now owns 4,269 shares of the company’s stock valued at $1,104,000 after purchasing an additional 37 shares during the period. Silver Coast Investments LLC raised its holdings in shares of Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock valued at $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management boosted its position in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after acquiring an additional 39 shares during the last quarter. Finally, Kwmg LLC boosted its holdings in shares of Johnson & Johnson by 1.7% during the third quarter. Kwmg LLC now owns 2,383 shares of the company’s stock worth $631,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.2%

NYSE:JNJ opened at $283.69 on Friday. The company has a market capitalization of $682.93 billion, a price-to-earnings ratio of 42.98, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22. The stock has a 50-day simple moving average of $266.83 and a 200 day simple moving average of $249.54. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $193.45 and a one year high of $286.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Top Johnson & Johnson Stories

Investors following JNJ have been watching these stories:

• Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
• Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Royal Bank Of Canada reduced their target price on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Morgan Stanley lowered their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday, October 15th. Finally, Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $275.92.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.